SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin, Matrix face antitrust probe in EU

09 Jul 2009 Evaluate
`

The bad times that the Indian pharmaceutical industry has been facing overseas are about to turn worse. Lupin Ltd, Matrix Laboratories and Niche Generics, the UK subsidiary of Unichem Laboratories, may face antitrust investigations by the European Union for delaying the entry into the market of generic versions of a hypertension drug.

 

The European Union’s antitrust regulator, the European Commission, said the three Indian companies, along with France’s Les Laboratories Servier, Israel-based Teva Laboratories and Krka Group, had entered into agreements to delay the entry of generic versions of Perindopril, on which Laboratories Servier had the patent. The market in Europe for Perindopril is worth $400 million.

 

The drug regulators in the US and Europe have in recent times raised question marks over the practices followed by some big Indian drug makers. The European Commission had started these investigations 18 months ago, following complaints that non-branded drugs were slow coming into the market because generic drug makers were teaming with patent holding companies to delay launches.

crackcrack

Lupin Share Price

2325.00 -3.60 (-0.15%)
21-Apr-2026 10:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.05
Dr. Reddys Lab 1223.90
Cipla 1230.70
Zydus Lifesciences 929.55
Lupin 2325.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×